A carregar...
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
BACKGROUND: BRAF inhibitors are effective anticancer agents in BRAF-mutated melanomas. By contrast, evidences about sensitivity of thyroid carcinomas to BRAF inhibition are conflicting and it has been proposed that BRAF V600E thyroid carcinoma cells are less sensitive to BRAF inhibitors due to activ...
Na minha lista:
Publicado no: | Cancer Cell Int |
---|---|
Main Authors: | , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5628448/ https://ncbi.nlm.nih.gov/pubmed/29033690 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-017-0457-z |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|